文献速递间质性肺疾病

尼达尼布治疗儿童和青少年纤维化性间质性肺疾病

Nintedanib in children and adolescents with fibrosing interstitial lung diseases.
PubMed 文献 · Eur Respir J · 2023-02-02

InPedILD试验纳入6–17岁纤维化性间质性肺疾病患者,2:1随机接受尼达尼布或安慰剂24周后开放标签尼达尼布。体重依赖的剂量方案使尼达尼布暴露量与成人相似,安全性可接受。

要点

  • 体重依赖的尼达尼布剂量在儿童和青少年中暴露量与成人相似。
  • 双盲期两组不良事件发生率均为84.6%,腹泻在尼达尼布组更常见。
  • 第24周FVC占预计值百分比变化两组间无显著差异。

核心结论

  • 在儿童和青少年纤维化性间质性肺疾病中,体重依赖的尼达尼布剂量方案产生的暴露量与成人相似,安全性可接受。

研究设计与样本

  • InPedILD试验为随机、双盲、安慰剂对照试验,纳入6–17岁纤维化性间质性肺疾病患者,按2:1随机接受尼达尼布或安慰剂24周,随后开放标签尼达尼布。
  • 共26例患者接受尼达尼布,13例接受安慰剂。

主要发现

  • 尼达尼布稳态AUCτ,ss几何均值(几何变异系数)在6–11岁患者为175 µg·h·L-1(85.1%),在12–17岁患者为160 µg·h·L-1(82.7%)。
  • 双盲期两组不良事件发生率均为84.6%,尼达尼布组2例因不良事件停药。
  • 腹泻在尼达尼布组和安慰剂组的发生率分别为38.5%和15.4%。
  • 第24周FVC占预计值百分比变化校正均值±标准误在尼达尼布组为0.3±1.3%,安慰剂组为-0.9±1.8%。

临床怎么用

  • 儿童和青少年纤维化性间质性肺疾病可考虑采用体重依赖的尼达尼布剂量方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Childhood interstitial lung disease (ILD) comprises a spectrum of rare ILDs affecting infants, children and adolescents. Nintedanib is a licensed treatment for pulmonary fibrosis in adults. The primary objectives of the InPedILD trial were to determine the dose-exposure and safety of nintedanib in children and adolescents with fibrosing ILD. METHODS: Patients aged 6-17 years with fibrosing ILD on high-resolution computed tomography and clinically significant disease were randomised 2:1 to receive nintedanib or placebo for 24 weeks and then open-label nintedanib. Dosing was based on weight-dependent allometric scaling. Co-primary end-points were the area under the plasma concentration-time curve at steady state (AUCτ,ss) at weeks 2 and 26 and the proportion of patients with treatment-emergent adverse events at week 24. RESULTS: 26 patients received nintedanib and 13 patients received placebo. The geometric mean (geometric coefficient of variation) AUCτ,ss for nintedanib was 175 µg·h·L-1 (85.1%) in patients aged 6-11 years and 160 µg·h·L-1 (82.7%) in patients aged 12-17 years. In the double-blind period, adverse events were reported in 84.6% of patients in each treatment group. Two patients discontinued nintedanib due to adverse events. Diarrhoea was reported in 38.5% and 15.4% of the nintedanib and placebo groups, respectively. Adjusted mean±se changes in percentage predicted forced vital capacity at week 24 were 0.3±1.3% in the nintedanib group and -0.9±1.8% in the placebo group. CONCLUSIONS: In children and adolescents with fibrosing ILD, a weight-based dosing regimen resulted in exposure to nintedanib similar to adults and an acceptable safety profile. These data provide a scientific basis for the use of nintedanib in this patient population.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Deterding R, Young LR, DeBoer EM, et al. Nintedanib in children and adolescents with fibrosing interstitial lung diseases. Eur Respir J. 2023. PMID: 36041751. doi:10.1183/13993003.01512-2022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。